Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
Journal Title: Haematology International Journal - Year 2017, Vol 1, Issue 1
Abstract
1.1. Background: A significant survival prolongation was recently reported by adding idelalisib to rituximab (IR) compared with rituximab (R) in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). No direct data are available about the relative safety and effectiveness of IR versus other commonly used treatments. The economic impact of novel treatments for CLL is still unknown and no study ever attempted in assessing the benefit-for-cost of IR as compared with the several available treatment options. 1.2. Aim: To investigate the economic and clinical impact of IR in CLL 1.3. Objective: To understand the potential clinical and economic advantage of IR in CLL patients who failed one prior treatment line (i.e. refractory to or relapsed after prior treatment lines), as compared with immunotherapy and chemoimmunotherapy. 1.4. Methods: A treatment-sequence model was developed to estimate the incremental cost per QALY of IR versus R, bendamustine-rituximab (BR) and fludarabine cyclophosphamide-rituximab (FCR) in the second-line treatment setting (i.e. refractory to or relapsed after first-line therapy)in Italy. Tree Age 2015 software was used to simulate second-to-third line treatment sequences by a five-states Markov model: the model was run at monthly steps for 30years.Probabilities of progression were obtained from published randomized and phase II studies (Furman, et al. 2014, Awan, et al. 2014, Fisher, et al. 2011): data were adapted to a second-line setting according to a fixed hazard ratio of 1.4 between subsequent lines. The analysis was performed in the perspective of the Italian national health-care system. 1.5. Results: Base case analysis reported that IR improved quality-adjusted life expectancy by 1.91, 1.41 and 0.86 years as compared with R, BR and FCR. The incremental cost per quality-adjusted year (QALY) was €2,993, €16,045 and €28,045, respectively. The main drivers of the model were: time horizon, idelalisib unit cost and treatment duration. Deterministic and probabilistic sensitivity analyses showed that treatment with IR was cost-effective at conventional willingness-to-pay threshold (€40,000 per QALY). 1.6. Conclusion: Based in this model, IR is a cost-effective option for CLL patients who deserve a second-line treatment.
Authors and Affiliations
Monia Marchetti
Keywords
Related Articles
- EP ID EP291037
- DOI -
- Views 108
- Downloads 0
Transfusion Support and Red Cell Alloimmunisation in Thalassemia Patients
Thalassemias are the most common mono genetic disease worldwide. It has high frequency extending from the Mediterranean basin through the Middle East (Iran), India and Southeast Asia. In India, the carrier rate of Beta T...
Management of Adult Onset Familial Hemophagocytic Lymphohistiocytosis (FHL): A Dilemma
Background: Perforin gene (PRF1) mutations cause the familial form of hemophagocytic lymphohistiocytosis (HLH). Case presentation: Here, we report a 36-year-old male with familial HLH, who was initially thought to be se...
Cladribine an Alternative for Midostaurine in FLT3 Positive Acute Myeloid Leukemia
Midostaurinis registered for the indication newly diagnosed acute myeloid leukemia that is FLT3 mutation positive in combination with standard cytarabine and daunorubicine induction and cytarabine consolidation. The regi...
Knowledge, Perception and Opinion of Health Workers on Bone Marrow Transplantation in Nigeria
1.1. Background: Bone marrow transplantation (BMT) or haematopoietic stem cell transplantation (HSCT) is a procedure used to cure haematopoietic malignancies, poorly functioning haematopoietic or immune system and geneti...
Ferritin Level in Pre and Postmenopausal Women Attending Usmanu Danfodiyo University Teaching Hospital Sokoto
Healthy individuals possess 3-4g of iron in his/her iron store, mostly in haemoglobin (oxygen-carrying pigment of blood) which is the most essential requirement of blood. Ferritin is a ubiquitous intracellular protein th...